echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Local gene therapy in vivo for recessive dystrophic epidermolysis bullosa

    Local gene therapy in vivo for recessive dystrophic epidermolysis bullosa

    • Last Update: 2022-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Summary

    Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong inherited skin disorder associated with blisters, lesions, and scarring caused by mutations in the COL7A1 gene, which encodes the anchoring fibrous component, collagen VII (C7)


    main

    Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating rare inherited skin disease with an incidence of 135 per million in the United States


    Many early C7 replacement strategies have been evaluated for RDEB8


    In vivo direct gene transfer for the treatment of inherited skin diseases has been a long-standing unrealized goal in the field of gene therapy


    The large ~9 kb COL7A1 transgene required for RDEB skin correction presents additional challenges for vector engineering


    We describe here the development and clinical translation of a localized gene therapy for RDEB that can be reapplied without serious adverse events


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.